Imagine a world where lost vision could be restored. A new groundbreaking study might just turn this dream into reality, ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

Painful diabetic neuropathy was associated with lower quality of life and higher rates of depression and anxiety than painless diabetic neuropathy.

Cleckheaton Health Centre has become the latest surgery to partner with the West Riding and Craven Diabetic Eye Screening ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

The FDA told Regeneron in a complete response letter that while it didn't identify any issues with the safety or efficacy of the drug in its approved indications and dosing regimens, the agency didn't ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.